Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A wave of promising data is transforming how doctors treat IgA nephropathy (IgAN), a leading cause of kidney failure. Interim phase III analyses of three investigational agents — povetacicept, ravulizumab, and sefaxersen — each showed dramatic proteinuria reductions of ~43–52% versus placebo. Meanwhile, final 2-year data from the ORIGIN and VISIONARY trials confirmed that atacicept and sibeprenlimab meaningfully slow kidney function decline, paving the way for full FDA approvals.
It's a big moment for IgA nephropathy treatment. Data from five separate phase III trials, all presented at ASN Kidney Week in Denver, paint a compelling picture of a disease that's finally meeting its match. Three drugs — povetacicept, ravulizumab (Ultomiris), and sefaxersen — delivered striking proteinuria reductions in interim analyses, while atacicept (Trutakna) and sibeprenlimab (Voyxact) confirmed they can actually slow kidney function decline in their final 2-year readouts.
The interim results are notable for their consistency: all three agents cut proteinuria by roughly 43–52% versus placebo, with favorable safety profiles. Ravulizumab recently received FDA accelerated approval for IgAN, while povetacicept has a PDUFA date of November 30. The final ORIGIN and VISIONARY data are being submitted to the FDA to support full (traditional) approvals for atacicept and sibeprenlimab, respectively.
By the Numbers
Why it matters: IgAN has long lacked disease-modifying therapies. This cluster of positive trials signals a paradigm shift — from supportive care to targeted immune-based treatment — offering real hope for patients at risk of progressing to kidney failure.
